A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity
Latest Information Update: 18 Nov 2024
At a glance
- Drugs BMS 986368 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Celgene Corporation
Most Recent Events
- 12 Nov 2024 Status changed from recruiting to completed.
- 20 Jun 2024 Status changed from not yet recruiting to recruiting.
- 15 May 2024 New trial record